NCR Online Journal

Ulcerative Colitis Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Space

 Breaking News
  • No posts were found

Ulcerative Colitis Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Space

November 18
17:56 2021
Ulcerative Colitis Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Space
DelveInsight Business Research LLP
DelveInsight’s “Ulcerative Colitis (UC) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Ulcerative Colitis (UC), historical and forecasted epidemiology as well as the Ulcerative Colitis (UC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Ulcerative Colitis – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Ulcerative Colitis – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Ulcerative Colitis, historical and forecasted epidemiology as well as the Ulcerative Colitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Ulcerative Colitis Market Report:

  • As per DelveInsight’s analysis, the total diagnosed cases of UC in the 7MM were 1,577,979 in 2020.

  • In the 7MM, the age-specific diagnosed cases of UC were 946,787, 441,834, 173,578, and 15,780 for the age group less than 18–44 years, 45–64 years, 65–84 years, and ≥85 years, in 2020. 

  • According to DelveInsight’s analysis, in the 7MM, 710,091 mild and 867,888 moderate-to-severe cases of UC were observed in 2020.

  • In the 7MM, the total treated cases of UC were observed as 781,100 cases in 2020, which is expected to rise in the coming years.

Key benefits of the report:

  1. Ulcerative Colitis market report covers a descriptive overview and comprehensive insight of the Ulcerative Colitis Epidemiology and Ulcerative Colitis  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

  2. The Ulcerative Colitis market report provides insights on the current and emerging therapies.

  3. Ulcerative Colitis market report provides a global historical and forecasted market covering drug outreach in 7MM.

  4. The Ulcerative Colitis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Ulcerative Colitis market.

Got queries? Click here to know more about the Ulcerative Colitis Market Landscape.

Ulcerative Colitis Overview

Inflammatory Bowel Disease (IBD) is an umbrella term used to describe disorders that involve chronic inflammation of the digestive tract. The exact cause of IBD is unknown, but it is the result of a defective immune system.

Two major types of IBD are Ulcerative Colitis (UC) and Crohn’s Disease (CD). UC is limited to the colon or large intestine. CD, on the other hand, can involve any part of the gastrointestinal tract from the mouth to the anus. Approximately 10% of cases of IBD exhibit the features of both CD and UC. These are typically known as Indeterminate Colitis (IC).

There are different types of UC, categorized by the cause of the disease: Ulcerative proctitis, Proctosigmoiditis, Left-sided colitis (also limited or distal colitis), Pancolitis, and Extensive Colitis.

Ulcerative Colitis Market 

The dynamics of the Ulcerative Colitis market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as AbbVie and Boehringer Ingelheim, Eli Lilly and Company, Janssen, Galapagos/Gilead, Theravance Biopharma, and Janssen, Arena, Landos Biopharma, and others during the forecasted period 2018-2030.

Ulcerative Colitis Pipeline Therapies and Key Companies 

  • Risankizumab (ABBV-066): AbbVie and Boehringer Ingelheim

  • Mirikizumab (LY3074828): Eli Lilly and Company

  • Tremfya (Guselkumab): Janssen

  • Filgotinib: Galapagos/Gilead

  • Izencitinib (TD-1473): Theravance Biopharma and Janssen 

  • Etrasimod (APD334): Arena

  • BT-11: Landos Biopharma

Ulcerative Colitis Market Drivers 

  • Involvement of Digital technology 

  • Rich emerging pipeline

  • Increasing Prevalence of Ulcerative Colitis 

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Ulcerative Colitis Patient Share (%) Overview at a Glance

5. Ulcerative Colitis Market Overview at a Glance

6. Ulcerative Colitis Disease Background and Overview

7. Ulcerative Colitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Ulcerative Colitis 

9. Ulcerative Colitis Current Treatment and Medical Practices

10. Unmet Needs

11. Ulcerative Colitis Emerging Therapies

12. Ulcerative Colitis Market Outlook

13. Country-Wise Ulcerative Colitis Market Analysis (2018-2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Ulcerative Colitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Ulcerative Colitis Market Outlook 2030. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles